In Vivo Pharmacodynamic Evaluation of ALT-Induced Asthma Model (CAT#: STEM-AE-0673-LGZ)

Asthma is a chronic airway inflammatory disease characterized by variable airflow obstruction, airway hyperreactivity (AHR) and airway inflammation. The main clinical symptoms of asthma are shortness of breath, wheezing, coughing and increased mucus production after exposure to allergens. Its pathogenesis is caused by a complex interaction between genetic, epigenetic and environmental factors. The different pathological changes are mediated by airway epithelial cells, eosinophils, and T lymphocyte subsets, among which Th2 cells are thought to predominate in hypereosinophilic asthma with elevated levels of cytokines IL-4, IL-5, and IL-13. The classic mouse asthma model is the airway inflammation model induced by ovalbumin (OVA). The mice were sensitized by multiple intrabitoneal injection of OVA and stimulated by atomizing inhalation of OVA to establish the acute asthma model. Serum IgE and eosinophilic granulocyte levels in alveolar lavage fluid increased, and pathological tissue section staining showed increased airway mucus and inflammatory leukocyte infiltration.
Experimental Animals: C57BL/6, Balb/c, B-hIL33/hST2 mice
Modeling reagent: ALT (Alternaria )
Modeling method: Sensitization—1-5 days; Challenge—19-26days

Autoimmune Disease

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

• Sample Type: liquid or powder